Oct 2026· Cancer Treatment and Research Communications· Vol 49, pp.
101468
· 0 citations· 47 references
Medicine
TL;DR
Sarcopenia preoperative is associated with higher risk of morbidity and the concept of assessment in wasting muscle quantity following pancreatectomy is essential for accurate long-term prognosis in resectable PC patients.
Abstract
Objective
To clarify the impact of preoperative sarcopenia and muscle wasting postoperative on the short- and long-term outcomes following pancreatectomy in resectable pancreatic cancer (PC) patients.
SUMMARY
Background
DATA
Previous studies revealed that sarcopenia, defined as generalized loss of skeletal muscle mass, was a poor prognosis factor following surgery. However, research focus on postoperative muscle wasting and their influences on the prognosis in resectable PC was very limited.
Methods
Retrospective analysis was performed for 284 early-stage PC patients who underwent pancreatic resection in two medical centers. Preoperative psoas major area and the degree of muscle reduction postoperative 3 months were calculated by computed tomography to define sarcopenia and drastic muscle wasting. Patients were assigned to 2 groups based on the presence or absence of sarcopenia or drastic muscle wasting and compared for postoperative morbidity and survival rate.
Results
Sarcopenia was present in 149 of 284 patients (52.4%), and a total of 88 patients (31.0%) developed muscle wasting of over 17% postoperatively. Compared with non-sarcopenia group, patients with sarcopenia had significantly greater incidence of overall or major morbidity (P = 0.001; P = 0.038, respectively), while sarcopenia status didn't correlate with poor-long term survival (DFS, P = 0.812; OS, P = 0.238). Surprisingly, patients presented drastic muscle wasting displayed poor DFS (P < 0.001) and OS (P < 0.001) and were found to be independent predictors of unfavorable DFS (P = 0.005) and OS (P < 0.001) after adjusting for clinicopathologic parameters.
Conclusions
Sarcopenia preoperative is associated with higher risk of morbidity. Moreover, the concept of assessment in wasting muscle quantity following pancreatectomy is essential for accurate long-term prognosis in resectable PC patients.
BACKGROUND
Sarcopenia, the loss of skeletal muscle mass and function, is an adverse prognostic factor in oncology. The computed tomography-derived skeletal muscle index (SMI) is a pragmatic surrogate of muscle mass, but contemporary data on its impact on survival and perioperative outcomes after radical cystectomy rema...
Benso John, J. Casuscelli, Alexander Buchner et al.· Clinical Genitourinary Cance...· 0 citations
BACKGROUND
Sarcopenia, defined as loss of muscle mass and function, has been identified as a negative prognostic factor in outcomes of major abdominal cancer operations. We sought to understand the impact of sarcopenia, using the psoas muscle index (PMI) as a surrogate, during neoadjuvant radiation (NR) on perioperativ...
L. Hendrick, Jae Hwan Choi, Rikesh J. Makanji et al.· Journal of Surgical Oncology· 0 citations
Background: Sarcopenia, characterized by progressive loss of skeletal muscle mass and strength, has emerged as a clinically significant factor influencing surgical outcomes. It is increasingly recognized as a predictor of morbidity and prolonged recovery in patients undergoing major abdominal procedures. However, limit...
Karpagavel Chandrabose, R. JeyaGanesh, V. Kumar· International Journal of Med...· 0 citations
: Introduction: The aim of the study was to investigate the influence of sarcopenia and hypoalbuminemia on overall survival in patients with esophageal cancer.
METHODS
Data from 138 patients treated for esophageal cancer at the Institute of Radiation Oncology, Bulovka University Hospital, Prague, Czech Republic, betw...
K. Votavová, R. Lohynská, T. Drbohlavová et al.· Oncology· 0 citations
BACKGROUND & AIMS
Body weight (BW) loss after gastrectomy is commonly monitored, but it may not accurately reflect skeletal muscle depletion. We investigated the prognostic significance of postoperative CT-defined muscle loss after curative gastrectomy, with RFS as the primary endpoint.
METHODS
We retrospectively ana...
S. Urakawa, T. Hirao, F. Moriwaki et al.· Clinical Nutrition ESPEN· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.